Richmond Pharmacology (RPL) will be attending this month's 22nd Annual DIA EuroMeeting, taking place 8-10 March 2010 in Monaco.

Posted:
1
March 2010

Richmond Pharmacology (RPL) will be attending this month�s 22nd Annual DIA EuroMeeting, taking place 8-10 March 2010 in Monaco.The DIA Annual EuroMeeting features more than 110 hot-topic sessions across 13 themes and attracts more than 3,000 professionals from the biopharmaceutical industry, contract service organisations, regulatory agencies, health ministries and academia, as well as patients and students worldwide.Themes are based on an integrated multidisciplinary approach that will generate interest from as many disciplines as possible. This year�s themes include:

  • Innovation
  • Staying in Business: How to Make Sure You Comply with All Rules and Regulations
  • Paediatric Medicines on Their Way to Patients
  • Decision Making: The Key to Efficient and Effective Drug Development, approval, and access
  • Paving the Way for Advanced Therapies: Fostering New Generations of Biotechnology-Derived Medicines
  • Challenges for Switching from Prescription to Non-Prescription Status through the Centralised Procedure
  • Personalised Medicines: What Is It, Where Do We Stand, and Where Are We Going?
  • Taking the European Regulatory Infrastructure Forward
  • Risk Management
  • The Informed Patient
  • eHealth
  • Pharmaceutical Sciences in 2020
  • Handling Clinical Trials, eSubmissions and Quality Requests

Click here to download advanced programme.RPL will be exhibiting at this year�s DIA EuroMeeting to inform key decision makers in the industry of our expertise and experience in the field of Early Phase Research. The EuroMeeting is a key event in the calendar and this forum provides an ideal opportunity to meet with existing clients, network and connect with new prospective sponsors. Planning to attend? We look forward to seeing you in Monaco next month!

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more